Las Vegas, NV -- (SBWIRE) -- 12/09/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: J.C. Penney Company, Inc.(NYSE:JCP), Twitter Inc(NYSE:TWTR), MannKind Corporation(NASDAQ:MNKD), Celgene Corporation (NASDAQ:CELG)
J.C. Penney Company, Inc.(NYSE:JCP) increased 3.84% at the price of $8.39 recently on a traded volume of 10.56 million shares, in comparison to 40.96 million shares of average trading volume. So far this year, the stock is down over -57.28%.
The company has a total market capitalization of $2.57 billion and its total outstanding shares are 304.62 million. J. C. Penney Company, Inc. (jcpenney) is a holding company. The Company is a retailer, operating 1,102 department stores in 49 states and Puerto Rico as of January 28, 2012. Its business consists of selling merchandise and services to consumers through its department stores and through its Internet Website at jcp.com.
For How Long JCP will Fight for Profitability ? Read This Trend Analysis report
Twitter Inc(NYSE:TWTR) soared 4.87% at the trading price of $47.14 on a traded volume of 4.09 million shares till now, whereas its average trading volume is 14.83 million shares. In the last three months, the stock is up 8.45%. The Intra-day range for the stock is $45.05 and $47.70. Twitter, Inc. (Twitter) is a global platform for public self-expression and conversation in real time. Twitter is a real-time platform, where any user can create a Tweet and any user can follow other users. Each Tweet is limited to 140 characters of text, but can also contain rich media,
For How Long TWTR Gloss will Attract Investors? Find out via this report
MannKind Corporation(NASDAQ:MNKD) jumped up 3.11% at the $5.28 recently. So far in three months, the stock is down -11.71%. The 52-week range for the stock is $2.04 and $8.70. Its introductory price for the day was $5.12, with the overall traded volume of 2.90 million shares. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company’s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia.
Will MNKD Continue To Move Higher? Find Out Here
Celgene Corporation (NASDAQ:CELG), after opening its shares at the price of $170.47, jumped up 119.57% , its recent trading price was $173.13 for the day. The stock moved on a traded volume of 2.18 million shares, in comparison to 2.82 million shares of average trading volume. The 52-week range for the stock is $77.22 and $173.80. Its introductory price for the day was $170.47. Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market.
Why Should Investors Buy CELG After The Recent Gain? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)